Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. - Wikidata - wikimedia - TriplyDB

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

http://www.wikidata.org/entity/Q37722935

about

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

http://www.wikidata.org/entity/Q37722935

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Etravirine combined with antir ...... 8 results of a phase IV trial.

@en

Etravirine combined with antir ...... 8 results of a phase IV trial.

@nl

type

label

Etravirine combined with antir ...... 8 results of a phase IV trial.

@en

Etravirine combined with antir ...... 8 results of a phase IV trial.

@nl

prefLabel

Etravirine combined with antir ...... 8 results of a phase IV trial.

@en

Etravirine combined with antir ...... 8 results of a phase IV trial.

@nl

P1433

Q37722935-6F3CEF3E-0E10-40E5-9A4F-B4CFAD68134F

P1476

Q37722935-52C7910A-E291-45E5-A8ED-A6D930798A62

P2093

Q37722935-01042047-5E73-4927-B82C-95B4476D444A

Q37722935-0427BCD7-C226-44BA-BB73-FA6D9C1BB241

Q37722935-09FD503D-F484-4736-9C5B-202E8B51DC7D

Q37722935-35021B69-02CD-49CD-A7D3-6281E9EE830F

Q37722935-6CAE87E3-5935-4D07-B393-6DE0070821DA

Q37722935-6EC9E1B0-2D57-4E17-831E-7C7D5A38566A

Q37722935-95ABFF64-F4DB-45BD-ACF5-1D8E453735C6

Q37722935-A1D26B33-CC01-4DBB-B7A7-FBF45D8D6E73

Q37722935-C8E564EC-743B-408A-89C3-E4A6A5F3A41C

P2860

Q37722935-010A0B0D-EC11-4781-A7AA-5F5D43D7004F

Q37722935-06E7CBC7-F1E8-4831-817B-2328CAFAE1D8

Q37722935-0AB6C240-3466-4D90-BE5D-7D3AE9693F85

Q37722935-0D364680-C543-4C5E-BF1C-33449F1A0C30

Q37722935-1A501660-41AB-47FA-989A-214801532756

Q37722935-212D3782-CC29-45F4-A2FF-9E778EFC6B1E

Q37722935-3548E749-9D8E-40EE-91BC-D28672057A69

Q37722935-3DA80564-742D-49B5-BEB7-BECF32DD3DCB

Q37722935-3FDB6BED-425E-4894-B346-4F7B3CEA8D6B

Q37722935-44D7D029-2E39-42D9-8E0D-57C105875349

P304

Q37722935-E8DA592D-D1B8-4930-8896-4D6529300153

P31

Q37722935-B3FBFFD5-31D8-4DB6-8F77-97333A379211

P356

Q37722935-74427734-6815-4966-8BF6-7FCB9E3D7BF1

P478

Q37722935-780BB2A9-022D-44FF-8530-200AAC606D15

P577

Q37722935-38D4F5ED-3609-4CE9-B8BC-EF0B97D42978

P698

Q37722935-C756C25A-DC06-4EC4-B86E-707794B39CD8

P921

Q37722935-0754337D-C113-4042-9E3B-E51DA8881857

Q37722935-2DDD8235-7864-4037-AAEA-B56FF74451D7

P932

Q37722935-19A05E65-72AC-4A8B-8FC7-E03B1352DA58

P356

2050312116686482

P1433

SAGE open medicine

P1476

Etravirine combined with antir ...... 8 results of a phase IV trial.

@en

P2093

Asad Bhorat

http://www.w3.org/2001/XMLSchema#string

Ben Van Baelen

http://www.w3.org/2001/XMLSchema#string

Eduardo Arathoon

http://www.w3.org/2001/XMLSchema#string

Herta Crauwels

http://www.w3.org/2001/XMLSchema#string

Lotke Tambuyzer

http://www.w3.org/2001/XMLSchema#string

Ludo Lavreys

http://www.w3.org/2001/XMLSchema#string

Magda Opsomer

http://www.w3.org/2001/XMLSchema#string

Rodica Silaghi

http://www.w3.org/2001/XMLSchema#string

Simon Vanveggel

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.

Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

Clinical pharmacokinetics and pharmacodynamics of etravirine.

P304

2050312116686482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2050312116686482

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28382208

http://www.w3.org/2001/XMLSchema#string

P921

phase IV clinical trial

antiretroviral drug

P932

5367767

http://www.w3.org/2001/XMLSchema#string